- United States
- /
- Medical Equipment
- /
- NYSE:MDT
Medtronic Full Year 2025 Earnings: EPS Misses Expectations
Medtronic (NYSE:MDT) Full Year 2025 Results
Key Financial Results
- Revenue: US$33.5b (up 3.6% from FY 2024).
- Net income: US$4.66b (up 27% from FY 2024).
- Profit margin: 14% (up from 11% in FY 2024).
- EPS: US$3.63 (up from US$2.77 in FY 2024).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Medtronic EPS Misses Expectations
Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 11%.
Looking ahead, revenue is forecast to grow 4.8% p.a. on average during the next 3 years, compared to a 8.1% growth forecast for the Medical Equipment industry in the US.
Performance of the American Medical Equipment industry.
The company's shares are down 1.1% from a week ago.
Risk Analysis
Be aware that Medtronic is showing 1 warning sign in our investment analysis that you should know about...
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About NYSE:MDT
Medtronic
Develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally.
Undervalued with excellent balance sheet and pays a dividend.
Similar Companies
Market Insights
Weekly Picks

When GPS fails: this small cap is fixing a $54B drone problem
From AI Infrastructure Plumber to Full-Stack AI Factory Architect

Aurelia Metals Limited — Transitioning Into a Higher-Quality Mid-Tier Producer

Is This strategic transformation of TTE? Significant re-rating potential
Recently Updated Narratives
Hotel101 Global: A Scalable Hospitality Platform Built to Compound

Cobre Limited Deep Dive: Can Sierra Atacama Unlock a Producer-Level Copper Valuation?
Classic Value Trap
Popular Narratives
NVIDIA will see a profit margin surge of 55% in the next 5 years

Analyst Commentary Highlights Microsoft AI Momentum and Upward Valuation Amid Growth and Competitive Risks


